SCHEDULE: DeepCurrents Discloses 7.7% Stake in Gossamer Bio

DeepCurrents Investment Group LLC and affiliates have reported a 7.7% beneficial ownership stake in Gossamer Bio, Inc. via a Schedule 13G filing.

Summary

• DeepCurrents Investment Group LLC, along with its affiliates and Kai Zheng, reported beneficial ownership of 37,665,073 shares of Gossamer Bio, Inc. common stock.
• This holding represents approximately 7.7% of the company's total outstanding shares, based on 488,846,722 shares outstanding as of June 5, 2026.
• The shares are held across the DCIG Capital Master Fund LP and a separately managed account.
• The filing is a passive investment disclosure under Schedule 13G, indicating the shares were not acquired to change or influence control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; it is a standard regulatory disclosure of existing ownership rather than a new strategic development or financial result.

Positives

• Institutional investor confidence demonstrated by a significant 7.7% equity position.
• The filing confirms the investment is passive, suggesting no immediate intent to disrupt corporate strategy or management.

Negatives

• Increased concentration of ownership may lead to higher stock volatility if the fund decides to rebalance its portfolio in the future.

Risks

• Market risk associated with the underlying performance of Gossamer Bio, Inc.
• Potential for future divestment by the reporting persons which could exert downward pressure on the share price.

Future Outlook

The filing does not provide forward-looking guidance for the issuer, as it is a standard disclosure of beneficial ownership by an institutional investor.

Management Comments

• The reporting persons certify that the securities were not acquired for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that institutional accumulation in mid-cap biotechnology firms often signals long-term confidence in the company's clinical pipeline or potential for M&A activity, though this specific filing is a standard passive disclosure.

Comparison to Industry Standards

• The filing follows standard SEC regulatory requirements for institutional investors exceeding the 5% ownership threshold.
• The use of a Joint Filing Agreement is standard practice for investment groups managing multiple entities or funds to streamline reporting.

Stakeholder Impact

• Shareholders may view the entry or disclosure of a 7.7% institutional holder as a sign of stability or potential support for the stock price.

Next Steps

• The reporting persons are required to file amendments to this statement if there are any material changes in the percentage of ownership.

Key Dates

Keywords

Gossamer Bio, DeepCurrents Investment Group, Schedule 13G, Institutional Ownership, Biotech Investment, Kai Zheng